In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a ...

MIRA Pharmaceuticals (MIRA) announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain.

MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...

Mar. 5, 2025 — People who take over-the-counter pain relievers after a concussion may recover faster than those who do not take pain relievers, according to a preliminary ... Compound Harnesses ...

For the nearly 20% of adults battling chronic pain daily, each morning brings the same question: Will today hurt less than ...

Discover the distinctive symptoms of liver pain, common underlying conditions, and effective treatment options to protect ...

Overview: Your patient presents with pain, swelling and impaired knee function. One rare diagnosis is non-malignant ...

U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...

Arthritis is a chronic condition that affects millions of people worldwide, causing pain, stiffness, and inflammation in the joints.

MIRA Pharmaceuticals gains approval for a Phase 1 trial of Ketamir-2 in Israel, aiming to complete by Q4 2025 before moving ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the approval and ...